CareLit · DOI-Nachweis · Geburtshilfe und Frauenheilkunde
Paclitaxel-carboplatin-gemcitabine (TCG) versus paclitaxel-carboplatin (TC) as first line treatment in women with ovarian cancer: A randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)
DOI 10.1055/s-2006-952195
Bibliografische Angaben
Nachweis in CareLit
Autor:innenAK Stähle, C Jackisch, B Schmalfeldt, S Loibl, K Wollschläger, HJ Lück, U Canzler, A duBois
ZeitschriftGeburtshilfe und Frauenheilkunde
Ausgabe09/2006
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: Ovarian cancer is still not curable in the majority of patients. Addition of non cross-resistant drugs to standard TC is a potential option for improvement of efficacy. G showed good activity in recurrent ovarian cancer. In phase II trials G cood be added to TC with manegeable toxicity. Therefore, a prospectively randomized phase III Intergroup study comparing TCG to standard TC was initiated within the GCIG n…
Zitieren
Zitierempfehlung
AK Stähle, C Jackisch, B Schmalfeldt, S Loibl, K Wollschläger, HJ Lück, U Canzler, A duBois (2006) Paclitaxel-carboplatin-gemcitabine (TCG) versus paclitaxel-carboplatin (TC) as first line treatment in women with ovarian cancer: A randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102). Geburtshilfe und Frauenheilkunde (09). https://doi.org/10.1055/s-2006-952195
Mit CareLit weiterarbeiten